Table 1.
Characteristic | IgG Anti-survivin-positive, n = 25 | IgG Anti-survivin-negative, n = 36 |
---|---|---|
Female/male | 24/1 | 29/7 |
Age at onset, mean ± SD yrs | 40 ± 16 | 47 ± 17 |
Disease duration, mean ± SD yrs | 6.4 ± 8.2* | 4.9 ± 6.3 |
Disease pattern, no. with diffuse/limited SSc | 13/12 | 24/12 |
Clinical features | ||
Modified Rodnan TSS, mean ± SD points | 13.6 ± 10.9 | 14.0 ± 10.9 |
Pitting scars, % | 36 | 44 |
Diffuse pigmentation, % | 52 | 55 |
Contracture of phalanges, % | 40 | 50 |
Organ involvement | ||
Lung | ||
Pulmonary fibrosis, % | 48 | 41 |
VC, mean ± SD, % | 89 ± 26 | 94 ± 25 |
DLCO, mean ± SD, % | 58 ± 17 | 58 ± 20 |
Decreased VC, % | 36 | 33 |
Decreased DLCO, % | 68 | 66 |
Pulmonary hypertension, % | 4 | 18 |
Esophagus, % | 60 | 55 |
Heart, % | 12 | 13 |
Kidney, % | 16 | 19 |
Joint, % | 20 | 22 |
Muscle, % | 24 | 19 |
Laboratory findings | ||
Positive for anti-topoisomerase I antibody, % | 56 | 41 |
Positive for anti-centromere antibody, % | 36 | 33 |
Serum IgG, mean ± SD mg/dl | 1712 ± 499 | 1641 ± 561 |
ESR, mean ± SD mm/h | 17.0 ± 11.5 | 17.7 ± 14.1 |
Serum survivin levels, mean ± SD pg/ml | 171 ± 53 | 181 ± 87 |
-
TSS: total skin thickness score; ESR: erythrocyte sedimentation rates; SSc: systemic sclerosis; VC: vital capacity; DLCO: diffusion capacity for carbon monoxide.
-
↵* p < 0.05 vs SSc patients without IgG anti-survivin antibody.